The DOI matches its Crossref record; 282 of the 282 references it cites were found in a registry or an index.
Emerging targets in cancer immunotherapy
Open accessAbstract
The first generation of immune checkpoint inhibitors (anti-CTLA-4 and anti-PD-1/PD-L1) targeted natural immune homeostasis pathways, co-opted by cancers, to drive anti-tumor immune responses. These agents led to unprecedented results in patients with previously incurable metastatic disease and may become first-line therapies for some advanced cancers. However, these agents are efficacious in only a minority of patients. Newer strategies are becoming available that target additional immunomodulatory mechanisms to activate patients' own anti-tumor immune responses. Herein, we present a succinct summary of emerging immune targets with reported pre-clinical efficacy that have progressed to active investigation in clinical trials. These emerging targets include co-inhibitory and co-stimulatory markers of the innate and adaptive immune system. In this review, we discuss: 1) T lymphocyte markers: Lymphocyte Activation Gene 3 [LAG-3], T-cell Immunoglobulin- and Mucin-domain-containing molecule 3 [TIM-3], V-domain containing Ig Suppressor of T cell Activation [VISTA], T cell ImmunoGlobulin and ITIM domain [TIGIT], B7-H3, Inducible T-cell Co-stimulator [ICOS/ICOS-L], CD27/CD70, and Glucocorticoid-Induced TNF Receptor [GITR]; 2) macrophage markers: CD47/Signal-Regulatory Protein alpha [SIRPα] and Indoleamine-2,3-Dioxygenase [IDO]; and 3) natural killer cell markers: CD94/NKG2A and the Killer Immunoglobulin-like receptor [KIR] family. Finally, we briefly highlight combination strategies and potential biomarkers of response and resistance to these cancer immunotherapies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
TIGIT predominantly regulates the immune response via regulatory T cells
Kurtulus, S., Sakuishi, K., Ngiow, S.-F., Joller, N., Tan, D. J., Teng, M. W. L., Smyth, M. J., Kuchroo, V. K., & Anderson, A. C. (2015) · Journal of Clinical Investigation · doi:10.1172/jci81187 · Cited by 551
RetractedChen, Y., Zhao, H., Zhu, D., Zhi, Q., He, S., Kuang, Y., Li, D., Zhang, Z., Song, S., Zhang, L., et al. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s66809 · Cited by 79
RetractedPembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism
Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I., Conway, S. J., Marshall, B., Brown, C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,585
Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305
Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation
Anderson, A. C., Joller, N., & Kuchroo, V. K. (2016) · Immunity · doi:10.1016/j.immuni.2016.05.001 · Cited by 2,096
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apetoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100643 · Cited by 2,072
The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057
Role of CD47 as a Marker of Self on Red Blood Cells
Oldenborg, P.-A., Zheleznyak, A., Fang, Y.-F., Lagenaur, C. F., Gresham, H. D., & Lindberg, F. P. (2000) · Science · doi:10.1126/science.288.5473.2051 · Cited by 1,970
Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.045 · Cited by 1,752
Willingham, S. B., Volkmer, J.-P., Gentles, A. J., Sahoo, D., Dalerba, P., Mitra, S. S., Wang, J., Contreras-Trujillo, H., Martin, R., Cohen, J. D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121623109 · Cited by 1,666
Woo, S.-R., Turnis, M. E., Goldberg, M. V., Bankoti, J., Selby, M., Nirschl, C. J., Bettini, M. L., Gravano, D. M., Vogel, P., Liu, C. L., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1620 · Cited by 1,647
Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism
Munn, D. H., Shafizadeh, E., Attwood, J. T., Bondarev, I., Pashine, A., & Mellor, A. L. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.9.1363 · Cited by 1,623
CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis
Jaiswal, S., Jamieson, C. H. M., Pang, W. W., Park, C. Y., Chao, M. P., Majeti, R., Traver, D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.046 · Cited by 1,581
Koyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms10501 · Cited by 1,580
Llosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487
ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28
Hutloff, A., Dittrich, A. M., Beier, K. C., Eljaschewitsch, B., Kraft, R., Anagnostopoulos, I., & Kroczek, R. A. (1999) · Nature · doi:10.1038/16717 · Cited by 1,482
Monney, L., Sabatos, C. A., Gaglia, J. L., Ryu, A., Waldner, H., Chernova, T., Manning, S., Greenfield, E. A., Coyle, A. J., Sobel, R. A., et al. (2002) · Nature · doi:10.1038/415536a · Cited by 1,472
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., Johnson, D. S., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,467
Losa, N. L., Cruise, M. W., Tam, A., Wick, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R., Fan, H., Wang, H., Luber, B. S., et al. (2014) · Journal of Immunotherapy for Cancer · doi:10.1186/2051-1426-3-s2-p410 · Cited by 1,408
Fourcade, J., Sun, Z., Benallaoua, M., Guillaume, P., Luescher, I. F., Sander, C., Kirkwood, J. M., Kuchroo, V., & Zarour, H. M. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100637 · Cited by 1,307
The Immunoreceptor TIGIT Regulates Antitumor and Antiviral CD8 + T Cell Effector Function
Johnston, R. J., Comps-Agrar, L., Hackney, J., Yu, X., Huseni, M., Yang, Y., Park, S., Javinal, V., Chiu, H., Irving, B., et al. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.018 · Cited by 1,194
Chao, M. P., Alizadeh, A. A., Tang, C., Myklebust, J. H., Varghese, B., Gill, S., Jan, M., Cha, A. C., Chan, C. K., Tan, B. T., et al. (2010) · Cell · doi:10.1016/j.cell.2010.07.044 · Cited by 1,087
Targeting natural killer cells in cancer immunotherapy
Guillerey, C., Huntington, N. D., & Smyth, M. J. (2016) · Nature Immunology · doi:10.1038/ni.3518 · Cited by 1,066
Muller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E., & Prendergast, G. C. (2005) · Nature Medicine · doi:10.1038/nm1196 · Cited by 1,064
B7-H3: A costimulatory molecule for T cell activation and IFN-γ production
Chapoval, A. I., Ni, J., Lau, J. S., Wilcox, R. A., Flies, D. B., Liu, D., Dong, H., Sica, G. L., Zhu, G., Tamada, K., et al. (2001) · Nature Immunology · doi:10.1038/85339 · Cited by 1,015
Nutt, C. L., Mani, D. R., Betensky, R. A., Tamayo, P., Cairncross, J. G., Ladd, C., Pohl, U., Hartmann, C. J., McLaughlin, M. E., Batchelor, T. T., et al. (2003) · PubMed · Cited by 959
Integrin-associated protein (CD47) and its ligands
Brown, E. (2001) · Trends in Cell Biology · doi:10.1016/s0962-8924(00)01906-1 · Cited by 878
Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection
Jin, H.-T., Anderson, A. C., Tan, W. G., West, E. E., Ha, S.-J., Araki, K., Freeman, G. J., Kuchroo, V. K., & Ahmed, R. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1009731107 · Cited by 858
Kamphorst, A. O., Pillai, R. N., Yang, S., Nasti, T. H., Akondy, R. S., Wieland, A., Sica, G. L., Yu, K., Koenig, L., Patel, N. T., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1705327114 · Cited by 854
Munn, D. H., Sharma, M. D., Hou, D., Baban, B., Lee, J. R., Antonia, S. J., Messina, J. L., Chandler, P., Koni, P. A., & Mellor, A. L. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21583 · Cited by 852
Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients
Baitsch, L., Baumgaertner, P., Devêvre, E., Raghav, S. K., Legat, A., Barba, L., Wieckowski, S., Bouzourene, H., Deplancke, B., Romero, P., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46102 · Cited by 845
TIGIT and PD-1 impair tumor antigen–specific CD8+ T cells in melanoma patients
Chauvin, J.-M., Pagliano, O., Fourcade, J., Sun, Z., Wang, H., Sander, C., Kirkwood, J. M., Chen, T.-H. T., Maurer, M., Korman, A. J., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80445 · Cited by 784
CD27 is required for generation and long-term maintenance of T cell immunity
Hendriks, J., Gravestein, L. A., Tesselaar, K., van Lier, R. A. W., Schumacher, T. N. M., & Borst, J. (2000) · Nature Immunology · doi:10.1038/80877 · Cited by 779
T-cell co-stimulation through B7RP-1 and ICOS
Yoshinaga, S. K., Whoriskey, J. S., Khare, S. D., Sarmiento, U., Guo, J., Horan, T., Shih, G., Zhang, M., Coccia, M. A., Kohno, T., et al. (1999) · Nature · doi:10.1038/45582 · Cited by 777
CD47 blockade triggers T cell–mediated destruction of immunogenic tumors
Liu, X., Pu, Y., Cron, K., Deng, L., Kline, J., Frazier, W. A., Xu, H., Peng, H., Fu, Y.-X., & Xu, M. M. (2015) · Nature Medicine · doi:10.1038/nm.3931 · Cited by 767
Jones, R. B., Ndhlovu, L. C., Barbour, J. D., Sheth, P. M., Jha, A. R., Long, B. R., Wong, J. C., Satkunarajah, M., Schweneker, M., Chapman, J. M., et al. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20081398 · Cited by 753
Gene Expression Profiling of Gliomas Strongly Predicts Survival
Freije, W. A., Castro-Vargas, F. E., Fang, Z., Horvath, S., Cloughesy, T., Liau, L. M., Mischel, P. S., & Nelson, S. F. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0452 · Cited by 744
Smith, J. J., Deane, N. G., Wu, F., Merchant, N. B., Zhang, B., Jiang, A., Lu, P., Johnson, J. C., Schmidt, C., Bailey, C. E., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.11.005 · Cited by 716
Sánchez-Fueyo, A., Tian, J., Picarella, D., Domenig, C., Zheng, X. X., Sabatos, C. A., Manlongat, N., Bender, O., Kamradt, T., Kuchroo, V. K., et al. (2003) · Nature Immunology · doi:10.1038/ni987 · Cited by 712
VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
Wang, L., Rubinstein, R., Lines, J. L., Wasiuk, A., Ahonen, C., Guo, Y., Lu, L.-F., Gondek, D., Wang, Y., Fava, R. A., et al. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20100619 · Cited by 710
Promotion of Tissue Inflammation by the Immune Receptor Tim-3 Expressed on Innate Immune Cells
Anderson, A. C., Anderson, D. E., Bregoli, L., Hastings, W. D., Kassam, N., Lei, C., Chandwaskar, R., Karman, J., Su, E. W., Hirashima, M., et al. (2007) · Science · doi:10.1126/science.1148536 · Cited by 701
Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression
Chung, C. H., Parker, J. S., Karaca, G., Wu, J., Funkhouser, W. K., Moore, D., Butterfoss, D., Xiang, D., Zanation, A., Yin, X., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00112-6 · Cited by 678
Intrinsic Gene Expression Profiles of Gliomas Are a Better Predictor of Survival than Histology
Gravendeel, L. A. M., Kouwenhoven, M. C. M., Gevaert, O., de Rooi, J. J., Stubbs, A. P., Duijm, J. E., Daemen, A., Bleeker, F. E., Bralten, L. B. C., Kloosterhof, N. K., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2307 · Cited by 678
Zhou, Q., Munger, M. E., Veenstra, R. G., Weigel, B. J., Hirashima, M., Munn, D. H., Murphy, W. J., Azuma, M., Anderson, A. C., Kuchroo, V. K., et al. (2011) · Blood · doi:10.1182/blood-2010-10-310425 · Cited by 675
Chan, K. S., Espinosa, I., Chao, M., Wong, D., Ailles, L., Diehn, M., Gill, H., Presti, J., Chang, H. Y., van de Rijn, M., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906549106 · Cited by 660
Sabatos, C. A., Chakravarti, S., Cha, E., Schubart, A., Sánchez-Fueyo, A., Zheng, X. X., Coyle, A. J., Strom, T. B., Freeman, G. J., & Kuchroo, V. K. (2003) · Nature Immunology · doi:10.1038/ni988 · Cited by 628
Gao, J., Ward, J. F., Pettaway, C. A., Shi, L. Z., Subudhi, S. K., Vence, L. M., Zhao, H., Chen, J., Chen, H., Efstathiou, E., et al. (2017) · Nature Medicine · doi:10.1038/nm.4308 · Cited by 594
Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer Immunotherapy
Picarda, E., Ohaegbulam, K. C., & Zang, X. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2428 · Cited by 582
The B7 family member B7-H3 preferentially down-regulates T helper type 1–mediated immune responses
Suh, W.-K., Gajewska, B. U., Okada, H., Gronski, M. A., Bertram, E. M., Dawicki, W., Duncan, G. S., Bukczynski, J., Plyte, S., Elia, A., et al. (2003) · Nature Immunology · doi:10.1038/ni967 · Cited by 576
Wainwright, D. A., Chang, A. L., Dey, M., Balyasnikova, I. V., Kim, C. K., Tobias, A., Cheng, Y., Kim, J. W., Qiao, J., Zhang, L., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0514 · Cited by 576
Ngiow, S. F., von Scheidt, B., Akiba, H., Yagita, H., Teng, M. W. L., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0096 · Cited by 574
Liakou, C. I., Kamat, A., Tang, D. N., Chen, H., Sun, J., Troncoso, P., Logothetis, C., & Sharma, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806075105 · Cited by 549
The CD28-Related Molecule ICOS Is Required for Effective T Cell–Dependent Immune Responses
Coyle, A. J., Lehar, S., Lloyd, C., Tian, J., Delaney, T., Manning, S., Nguyen, T., Burwell, T., Schneider, H., Gonzalo, J. A., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00011-x · Cited by 520
Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity
Ndhlovu, L. C., Lopez-Vergès, S., Barbour, J. D., Jones, R. B., Jha, A. R., Long, B. R., Schoeffler, E. C., Fujita, T., Nixon, D. F., & Lanier, L. L. (2012) · Blood · doi:10.1182/blood-2011-11-392951 · Cited by 514
Polymorphism in Sirpa modulates engraftment of human hematopoietic stem cells
Takenaka, K., Prasolava, T. K., Wang, J. C. Y., Mortin-Toth, S. M., Khalouei, S., Gan, O. I., Dick, J. E., & Danska, J. S. (2007) · Nature Immunology · doi:10.1038/ni1527 · Cited by 509
VISTA Regulates the Development of Protective Antitumor Immunity
Le Mercier, I., Chen, W., Lines, J. L., Day, M., Li, J., Sergent, P., Noelle, R. J., & Wang, L. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1506 · Cited by 486
Tsai, R. K., & Discher, D. E. (2008) · The Journal of Cell Biology · doi:10.1083/jcb.200708043 · Cited by 486
Pre-Clinical Development of a Humanized Anti-CD47 Antibody with Anti-Cancer Therapeutic Potential
Liu, J., Wang, L., Zhao, F., Tseng, S., Narayanan, C., Shura, L., Willingham, S., Howard, M., Prohaska, S., Volkmer, J., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0137345 · Cited by 475
Carthon, B. C., Wolchok, J. D., Yuan, J., Kamat, A., Ng Tang, D. S., Sun, J., Ku, G., Troncoso, P., Logothetis, C. J., Allison, J. P., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0569 · Cited by 460
B7h, a Novel Costimulatory Homolog of B7.1 and B7.2, Is Induced by TNFα
Swallow, M. M., Wallin, J. J., & Sha, W. C. (1999) · Immunity · doi:10.1016/s1074-7613(00)80117-x · Cited by 453
Fujioka, Y., Matozaki, T., Noguchi, T., Iwamatsu, A., Yamao, T., Takahashi, N., Tsuda, M., Takada, T., & Kasuga, M. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.12.6887 · Cited by 448
McAdam, A. J., Chang, T. T., Lumelsky, A. E., Greenfield, E. A., Boussiotis, V. A., Duke-Cohan, J. S., Chernova, T., Malenkovich, N., Jabs, C., Kuchroo, V. K., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.9.5035 · Cited by 440
TIGIT and CD 96: new checkpoint receptor targets for cancer immunotherapy
Dougall, W. C., Kurtulus, S., Smyth, M. J., & Anderson, A. C. (2017) · Immunological Reviews · doi:10.1111/imr.12518 · Cited by 435
Golden-Mason, L., Palmer, B. E., Kassam, N., Townshend-Bulson, L., Livingston, S., McMahon, B. J., Castelblanco, N., Kuchroo, V., Gretch, D. R., & Rosen, H. R. (2009) · Journal of Virology · doi:10.1128/jvi.00639-09 · Cited by 431
Reversal of NK-Cell Exhaustion in Advanced Melanoma by Tim-3 Blockade
da Silva, I. P., Gallois, A., Jimenez-Baranda, S., Khan, S., Anderson, A. C., Kuchroo, V. K., Osman, I., & Bhardwaj, N. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0171 · Cited by 424
CD27 and CD70 in T cell and B cell activation
Borst, J., Hendriks, J., & Xiao, Y. (2005) · Current Opinion in Immunology · doi:10.1016/j.coi.2005.04.004 · Cited by 419
Romagné, F., André, P., Spee, P., Zahn, S., Anfossi, N., Gauthier, L., Capanni, M., Ruggeri, L., Benson, D. M., Blaser, B. W., et al. (2009) · Blood · doi:10.1182/blood-2009-02-206532 · Cited by 408
The survival kinases Akt and Pim as potential pharmacological targets
Amaravadi, R. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26273 · Cited by 408
Brown, E., Hooper, L., Ho, T., & Gresham, H. (1990) · The Journal of cell biology · doi:10.1083/jcb.111.6.2785 · Cited by 407
Gao, X., Zhu, Y., Li, G., Huang, H., Zhang, G., Wang, F., Sun, J., Yang, Q., Zhang, X., & Lu, B. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030676 · Cited by 407
Zang, X., Thompson, R. H., Al-Ahmadie, H. A., Serio, A. M., Reuter, V. E., Eastham, J. A., Scardino, P. T., Sharma, P., & Allison, J. P. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709802104 · Cited by 401
Huang, R.-Y., Francois, A., McGray, A. R., Miliotto, A., & Odunsi, K. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1249561 · Cited by 388
Bogunovic, D., O'Neill, D. W., Belitskaya-Levy, I., Vacic, V., Yu, Y.-L., Adams, S., Darvishian, F., Berman, R., Shapiro, R., Pavlick, A. C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905139106 · Cited by 384
Lindberg, F. P., Gresham, H. D., Schwarz, E., & Brown, E. J. (1993) · The Journal of cell biology · doi:10.1083/jcb.123.2.485 · Cited by 379
Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase.
Takikawa, O., Yoshida, R., Kido, R., & Hayaishi, O. (1986) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)35696-x · Cited by 377
Hendriks, J., Xiao, Y., & Borst, J. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20030916 · Cited by 376
Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
Liu, J., Yuan, Y., Chen, W., Putra, J., Suriawinata, A. A., Schenk, A. D., Miller, H. E., Guleria, I., Barth, R. J., Huang, Y. H., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420370112 · Cited by 374
Gleason, M. K., Lenvik, T. R., McCullar, V., Felices, M., O'Brien, M. S., Cooley, S. A., Verneris, M. R., Cichocki, F., Holman, C. J., Panoskaltsis-Mortari, A., et al. (2012) · Blood · doi:10.1182/blood-2011-06-360321 · Cited by 373
Murine B7-H3 is a negative regulator of T cells
Prasad, D. V. R., Nguyen, T., Li, Z., Yang, Y., Duong, J., Wang, Y., & Dong, C. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.4.2500 · Cited by 368
Indoleamine 2,3‐dioxygenase contributes to tumor cell evasion of T cell‐mediated rejection
Friberg, M., Jennings, R., Alsarraj, M., Dessureault, S., Cantor, A., Extermann, M., Mellor, A. L., Munn, D. H., & Antonia, S. J. (2002) · International Journal of Cancer · doi:10.1002/ijc.10645 · Cited by 365
Théate, I., van Baren, N., Pilotte, L., Moulin, P., Larrieu, P., Renauld, J.-C., Hervé, C., Gutierrez-Roelens, I., Marbaix, E., Sempoux, C., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0137 · Cited by 363
The Yin and Yang of HLA and KIR in human disease
Kulkarni, S., Martin, M. P., & Carrington, M. (2008) · Seminars in Immunology · doi:10.1016/j.smim.2008.06.003 · Cited by 363
Yan, Y., Zhang, G.-X., Gran, B., Fallarino, F., Yu, S., Li, H., Cullimore, M. L., Rostami, A., & Xu, H. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1001628 · Cited by 358
Vstm3 is a member of the CD28 family and an important modulator of T‐cell function
Levin, S. D., Taft, D. W., Brandt, C. S., Bucher, C., Howard, E. D., Chadwick, E. M., Johnston, J., Hammond, A., Bontadelli, K., Ardourel, D., et al. (2011) · European Journal of Immunology · doi:10.1002/eji.201041136 · Cited by 356
Induction of tumor-specific T cell memory by NK cell–mediated tumor rejection
Kelly, J. M., Darcy, P. K., Markby, J. L., Godfrey, D. I., Takeda, K., Yagita, H., & Smyth, M. J. (2002) · Nature Immunology · doi:10.1038/ni746 · Cited by 356
Cells Expressing Indoleamine 2,3-Dioxygenase Inhibit T Cell Responses
Mellor, A. L., Keskin, D. B., Johnson, T., Chandler, P., & Munn, D. H. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.8.3771 · Cited by 348
Identification and Characterization of Galectin-9, a Novel β-Galactoside-binding Mammalian Lectin
Wada, J., & Kanwar, Y. S. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.9.6078 · Cited by 337
TIM‐3 is expressed on activated human CD4+ T cells and regulates Th1 and Th17 cytokines
Hastings, W. D., Anderson, D. E., Kassam, N., Koguchi, K., Greenfield, E. A., Kent, S. C., Zheng, X. X., Strom, T. B., Hafler, D. A., & Kuchroo, V. K. (2009) · European Journal of Immunology · doi:10.1002/eji.200939274 · Cited by 333
Tang, C., Welsh, J. W., de Groot, P., Massarelli, E., Chang, J. Y., Hess, K. R., Basu, S., Curran, M. A., Cabanillas, M. E., Subbiah, V., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1432 · Cited by 321
Soares, H., Waechter, H., Glaichenhaus, N., Mougneau, E., Yagita, H., Mizenina, O., Dudziak, D., Nussenzweig, M. C., & Steinman, R. M. (2007) · The Journal of Experimental Medicine · doi:10.1084/jem.20070176 · Cited by 316
Beatty, G. L., O'Dwyer, P. J., Clark, J., Shi, J. G., Bowman, K. J., Scherle, P. A., Newton, R. C., Schaub, R., Maleski, J., Leopold, L., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2272 · Cited by 314
Yang, Z.-Z., Grote, D. M., Ziesmer, S. C., Niki, T., Hirashima, M., Novak, A. J., Witzig, T. E., & Ansell, S. M. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59806 · Cited by 309
Huang, R.-Y., Eppolito, C., Lele, S., Shrikant, P., Matsuzaki, J., & Odunsi, K. (2015) · Oncotarget · doi:10.18632/oncotarget.4751 · Cited by 308
Shayan, G., Srivastava, R., Li, J., Schmitt, N., Kane, L. P., & Ferris, R. L. (2017) · OncoImmunology · doi:10.1080/2162402x.2016.1261779 · Cited by 306
Vonderheide, R. H., LoRusso, P. M., Khalil, M., Gartner, E. M., Khaira, D., Soulieres, D., Dorazio, P., Trosko, J. A., Rüter, J., Mariani, G. L., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0505 · Cited by 301
Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy
Fan, X., Quezada, S. A., Sepulveda, M. A., Sharma, P., & Allison, J. P. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20130590 · Cited by 300
B7‐H3 is a potent inhibitor of human T‐cell activation: No evidence for B7‐H3 and TREML2 interaction
Leitner, J., Klauser, C., Pickl, W. F., Stöckl, J., Majdic, O., Bardet, A. F., Kreil, D. P., Dong, C., Yamazaki, T., Zlabinger, G., et al. (2009) · European Journal of Immunology · doi:10.1002/eji.200839028 · Cited by 290
Tryptophan Pyrrolase of Rabbit Intestine
Yamamoto, S., & Hayaishi, O. (1967) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)99420-2 · Cited by 289
Development of an Fc-Enhanced Anti–B7-H3 Monoclonal Antibody with Potent Antitumor Activity
Loo, D., Alderson, R. F., Chen, F. Z., Huang, L., Zhang, W., Gorlatov, S., Burke, S., Ciccarone, V., Li, H., Yang, Y., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0715 · Cited by 284
Edris, B., Weiskopf, K., Volkmer, A. K., Volkmer, J.-P., Willingham, S. B., Contreras-Trujillo, H., Liu, J., Majeti, R., West, R. B., Fletcher, J. A., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121629109 · Cited by 258
Costimulation of T cells by B7-H2, a B7-like molecule that binds ICOS
Wang, S., Zhu, G., Chapoval, A. I., Dong, H., Tamada, K., Ni, J., & Chen, L. (2000) · Blood · doi:10.1182/blood.v96.8.2808 · Cited by 257
Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas
Zang, X., Sullivan, P. S., Soslow, R. A., Waitz, R., Reuter, V. E., Wilton, A., Thaler, H. T., Arul, M., Slovin, S. F., Wei, J., et al. (2010) · Modern Pathology · doi:10.1038/modpathol.2010.95 · Cited by 249
Flies, D. B., Wang, S., Xu, H., & Chen, L. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100660 · Cited by 249
DAP12-Based Activating Chimeric Antigen Receptor for NK Cell Tumor Immunotherapy
Töpfer, K., Cartellieri, M., Michen, S., Wiedemuth, R., Müller, N., Lindemann, D., Bachmann, M., Füssel, M., Schackert, G., & Temme, A. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1400330 · Cited by 249
Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma
Kramer, K., Kushner, B. H., Modak, S., Pandit-Taskar, N., Smith-Jones, P., Zanzonico, P., Humm, J. L., Xu, H., Wolden, S. L., Souweidane, M. M., et al. (2010) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-0038-7 · Cited by 247
Characterization of Human Inducible Costimulator Ligand Expression and Function
Aicher, A., Hayden-Ledbetter, M., Brady, W. A., Pezzutto, A., Richter, G., Magaletti, D., Buckwalter, S., Ledbetter, J. A., & Clark, E. A. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.9.4689 · Cited by 245
The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti–CTLA-4 Therapy
Fu, T., He, Q., & Sharma, P. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1138 · Cited by 243
Yamazaki, F., Kuroiwa, T., Takikawa, O., & Kido, R. (1985) · Biochemical Journal · doi:10.1042/bj2300635 · Cited by 243
Inducible costimulator promotes helper T-cell differentiation through phosphoinositide 3-kinase
Gigoux, M., Shang, J., Pak, Y., Xu, M., Choe, J., Mak, T. W., & Suh, W.-K. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0911573106 · Cited by 241
VISTA is a novel broad-spectrum negative checkpoint regulator for cancer immunotherapy
Lines, J. L., Sempere, L. F., Broughton, T., Wang, L., & Noelle, R. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0072 · Cited by 236
van Lier, R. A. W., Borst, J., Vroom, T. M., Klein, H., Van Mourik, P., Zeijlemaker, W. P., & Melief, C. J. M. (1987) · The Journal of Immunology · doi:10.4049/jimmunol.139.5.1589 · Cited by 232
In vivo expression of alternatively spliced forms of integrin-associated protein (cd47)
Reinhold, M. I., Lindberg, F. P., Plas, D., Reynolds, S., Peters, M. G., & Brown, E. J. (1995) · Journal of Cell Science · doi:10.1242/jcs.108.11.3419 · Cited by 232
Ling, V., Wu, P. W., Finnerty, H. F., Bean, K. M., Spaulding, V., Fouser, L. A., Leonard, J. P., Hunter, S. E., Zollner, R., Thomas, J. L., et al. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.4.1653 · Cited by 230
IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients
Sim, G. C., Martin-Orozco, N., Jin, L., Yang, Y., Wu, S., Washington, E., Sanders, D., Lacey, C., Wang, Y., Vence, L., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci46266 · Cited by 229
Enhanced suppressor function of TIM‐3+FoxP3+ regulatory T cells
Gautron, A., Dominguez‐Villar, M., de Marcken, M., & Hafler, D. A. (2014) · European Journal of Immunology · doi:10.1002/eji.201344392 · Cited by 228
Brignone, C., Escudier, B., Grygar, C., Marcu, M., & Triebel, F. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0068 · Cited by 226
Rationale for anti-GITR cancer immunotherapy
Knee, D. A., Hewes, B., & Brogdon, J. L. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.06.028 · Cited by 221
Control of lymphocyte function through CD27–CD70 interactions
Lens, S. M. A., Tesselaar, K., van Oers, M. H. J., & van Lier, R. A. W. (1998) · Seminars in Immunology · doi:10.1006/smim.1998.0154 · Cited by 219
HLA-E expression by gynecological cancers restrains tumor-infiltrating CD8+T lymphocytes
Gooden, M., Lampen, M., Jordanova, E. S., Leffers, N., Trimbos, J. B., van der Burg, S. H., Nijman, H., & van Hall, T. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1100354108 · Cited by 215
Williams, J. B., Horton, B. L., Zheng, Y., Duan, Y., Powell, J. D., & Gajewski, T. F. (2017) · Journal of Experimental Medicine · doi:10.1084/jem.20160485 · Cited by 210
Lee, Y., Scheck, A. C., Cloughesy, T. F., Lai, A., Dong, J., Farooqi, H. K., Liau, L. M., Horvath, S., Mischel, P. S., & Nelson, S. F. (2008) · BMC Medical Genomics · doi:10.1186/1755-8794-1-52 · Cited by 208
T Cell Apoptosis by Kynurenines
Fallarino, F., Grohmann, U., Vacca, C., Orabona, C., Spreca, A., Fioretti, M. C., & Puccetti, P. (2003) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4615-0135-0_21 · Cited by 204
Sarhan, D., Cichocki, F., Zhang, B., Yingst, A., Spellman, S. R., Cooley, S., Verneris, M. R., Blazar, B. R., & Miller, J. S. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0839 · Cited by 200
Expression of the Murine CD27 Ligand CD70 In Vitro and In Vivo
Tesselaar, K., Xiao, Y., Arens, R., van Schijndel, G. M. W., Schuurhuis, D. H., Mebius, R. E., Borst, J., & van Lier, R. A. W. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.170.1.33 · Cited by 198
Ge, K., DuHadaway, J., Du, W., Herlyn, M., Rodeck, U., & Prendergast, G. C. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.17.9689 · Cited by 195
Wang, L., Le Mercier, I., Putra, J., Chen, W., Liu, J., Schenk, A. D., Nowak, E. C., Suriawinata, A. A., Li, J., & Noelle, R. J. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1407447111 · Cited by 195
Molecular cloning and characterization of murine ICOS and identification of B7h as ICOS ligand
Mages, H. W., Hutloff, A., Heuck, C. J., Büchner, K., Himmelbauer, H., Oliveri, F., & Kroczek, R. A. (2000) · European Journal of Immunology · doi:10.1002/(sici)1521-4141(200004)30:4<1040::aid-immu1040>3.0.co;2-6 · Cited by 193
Khandelwal, S., Van Rooijen, N., & Saxena, R. K. (2007) · Transfusion · doi:10.1111/j.1537-2995.2007.01348.x · Cited by 187
Tim-3 Expression Defines Regulatory T Cells in Human Tumors
Yan, J., Zhang, Y., Zhang, J.-P., Liang, J., Li, L., & Zheng, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0058006 · Cited by 182
Bullock, T. N. J., & Yagita, H. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.710 · Cited by 182
Targeting NK-cell checkpoints for cancer immunotherapy
Muntasell, A., Ochoa, M. C., Cordeiro, L., Berraondo, P., López-Díaz de Cerio, A., Cabo, M., López-Botet, M., & Melero, I. (2017) · Current Opinion in Immunology · doi:10.1016/j.coi.2017.01.003 · Cited by 182
Luo, L., Chapoval, A. I., Flies, D. B., Zhu, G., Hirano, F., Wang, S., Lau, J. S., Dong, H., Tamada, K., Flies, A. S., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.9.5445 · Cited by 181
Induction, binding specificity and function of human ICOS
Beier, K. C., Hutloff, A., Dittrich, A., Heuck, C. J., Rauch, A. M., Büchner, K., Ludewig, B., Ochs, H. D., Mages, H. W., & Kroczek, R. A. (2000) · European Journal of Immunology · doi:10.1002/1521-4141(200012)30:12<3707::aid-immu3707>3.0.co;2-q · Cited by 180
Lu, L., Xu, X., Zhang, B., Zhang, R., Ji, H., & Wang, X. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-36 · Cited by 177
CD27 Defines Phenotypically and Functionally Different Human NK Cell Subsets
Vossen, M. T. M., Matmati, M., Hertoghs, K. M. L., Baars, P. A., Gent, M.-R., Leclercq, G., Hamann, J., Kuijpers, T. W., & van Lier, R. A. W. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.6.3739 · Cited by 176
Ling, V., Wu, P. W., Spaulding, V., Kieleczawa, J., Luxenberg, D., Carreno, B. M., & Collins, M. (2003) · Genomics · doi:10.1016/s0888-7543(03)00126-5 · Cited by 174
Grimbert, P., Bouguermouh, S., Baba, N., Nakajima, T., Allakhverdi, Z., Braun, D., Saito, H., Rubio, M., Delespesse, G., & Sarfati, M. (2006) · The Journal of Immunology · doi:10.4049/jimmunol.177.6.3534 · Cited by 174
Deng, W.-W., Mao, L., Yu, G.-T., Bu, L.-L., Ma, S.-R., Liu, B., Gutkind, J. S., Kulkarni, A. B., Zhang, W.-F., & Sun, Z.-J. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1239005 · Cited by 172
Wang, X.-Q., & Frazier, W. A. (1998) · Molecular Biology of the Cell · doi:10.1091/mbc.9.4.865 · Cited by 171
Cutting Edge: Accelerated Autoimmune Diabetes in the Absence of LAG-3
Bettini, M., Szymczak-Workman, A. L., Forbes, K., Castellaw, A. H., Selby, M., Pan, X., Drake, C. G., Korman, A. J., & Vignali, D. A. A. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1100714 · Cited by 169
Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy
Coe, D., Begom, S., Addey, C., White, M., Dyson, J., & Chai, J.-G. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-010-0866-5 · Cited by 168
Kim, I.-K., Kim, B.-S., Koh, C.-H., Seok, J.-W., Park, J.-S., Shin, K.-S., Bae, E.-A., Lee, G.-E., Jeon, H., Cho, J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3922 · Cited by 167
Carlsten, M., Korde, N., Kotecha, R., Reger, R., Bor, S., Kazandjian, D., Landgren, O., & Childs, R. W. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1108 · Cited by 166
Antibody mediated therapy targeting CD47 inhibits tumor progression of hepatocellular carcinoma
Xiao, Z., Chung, H., Banan, B., Manning, P. T., Ott, K. C., Lin, S., Capoccia, B. J., Subramanian, V., Hiebsch, R. R., Upadhya, G. A., et al. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.02.036 · Cited by 164
Apoptosis of tumor infiltrating effector TIM-3+CD8+ T cells in colon cancer
Kang, C.-W., Dutta, A., Chang, L.-Y., Mahalingam, J., Lin, Y.-C., Chiang, J.-M., Hsu, C.-Y., Huang, C.-T., Su, W.-T., Chu, Y.-Y., et al. (2015) · Scientific Reports · doi:10.1038/srep15659 · Cited by 163
Böger, C., Behrens, H., Krüger, S., & Röcken, C. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1293215 · Cited by 163
Keller, A. M., Schildknecht, A., Xiao, Y., van den Broek, M., & Borst, J. (2008) · Immunity · doi:10.1016/j.immuni.2008.10.009 · Cited by 160
Wu, L., Deng, W.-W., Huang, C.-F., Bu, L.-L., Yu, G.-T., Mao, L., Zhang, W.-F., Liu, B., & Sun, Z.-J. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-1968-0 · Cited by 158
Sanchez, P. J., McWilliams, J. A., Haluszczak, C., Yagita∥, H., & Kedl, R. M. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.3.1564 · Cited by 157
Arens, R., Schepers, K., Nolte, M. A., van Oosterwijk, M. F., van Lier, R. A. W., Schumacher, T. N., & van Oers, M. H. J. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031111 · Cited by 153
Melanoma Cells Express ICOS Ligand to Promote the Activation and Expansion of T-Regulatory Cells
Martín‐Orozco, N., Li, Y., Wang, Y., Liu, S., Hwu, P., Liu, Y., Dong, C., & Radvanyi, L. G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1379 · Cited by 150
Wang, F., Hou, H., Wu, S., Tang, Q., Liu, W., Huang, M., Yin, B., Huang, J., Mao, L., Lu, Y., et al. (2015) · European Journal of Immunology · doi:10.1002/eji.201545480 · Cited by 144
Yamauchi, T., Takenaka, K., Urata, S., Shima, T., Kikushige, Y., Tokuyama, T., Iwamoto, C., Nishihara, M., Iwasaki, H., Miyamoto, T., et al. (2013) · Blood · doi:10.1182/blood-2012-06-440354 · Cited by 143
Mahnke, K., Ring, S., Johnson, T., Schallenberg, S., Schönfeld, K., Storn, V., Bedke, T., & Enk, A. (2007) · European Journal of Immunology · doi:10.1002/eji.200636841 · Cited by 142
Scurr, M. J., Ladell, K., Besneux, M., Christian, A. D., Hockey, T., Smart, K., Bridgeman, H. M., Hargest, R., Phillips, S. M., Davies, M. M., et al. (2013) · Mucosal Immunology · doi:10.1038/mi.2013.62 · Cited by 142
CD27 Is Acquired by Primed B Cells at the Centroblast Stage and Promotes Germinal Center Formation
Xiao, Y., Hendriks, J., Langerak, P., Jacobs, H., & Borst, J. G. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.12.7432 · Cited by 141
Yamao, T., Noguchi, T., Takeuchi, O., Nishiyama, U., Morita, H., Hagiwara, T., Akahori, H., Kato, T., Inagaki, K., Okazawa, H., et al. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m203287200 · Cited by 140
Allograft rejection is restrained by short-lived TIM-3+PD-1+Foxp3+ Tregs
Gupta, S., Thornley, T. B., Gao, W., Larocca, R., Turka, L. A., Kuchroo, V. K., & Strom, T. B. (2012) · Journal of Clinical Investigation · doi:10.1172/jci45138 · Cited by 139
CD47 Mediates Killing of Breast Tumor Cells via Gi-Dependent Inhibition of Protein Kinase A
Manna, P. P., & Frazier, W. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-1708 · Cited by 139
Nagase, H., Takeoka, T., Urakawa, S., Morimoto-Okazawa, A., Kawashima, A., Iwahori, K., Takiguchi, S., Nishikawa, H., Sato, E., Sakaguchi, S., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30475 · Cited by 139
B7-H3 Associated with Tumor Progression and Epigenetic Regulatory Activity in Cutaneous Melanoma
Wang, J., Chong, K. K., Nakamura, Y., Nguyen, L., Huang, S. K., Kuo, C. T., Zhang, W., Yu, H., Morton, D. L., & Hoon, D. S. �. (2013) · Journal of Investigative Dermatology · doi:10.1038/jid.2013.114 · Cited by 137
Indoleamine 2,3-dioxygenase: distribution and function in the developing human placenta
Kudo, Y., Boyd, C. A. R., Spyropoulou, I., Redman, C. W. G., Takikawa, O., Katsuki, T., Hara, T., Ohama, K., & Sargent, I. L. (2004) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2003.11.004 · Cited by 137
Structure and T Cell Inhibition Properties of B7 Family Member, B7-H3
Vigdorovich, V. I., Ramagopal, U. A., Lázár‐Molnár, E., Sylvestre, E., Lee, J. S., Hofmeyer, K. A., Zang, X., Nathenson, S. G., & Almo, S. C. (2013) · Structure · doi:10.1016/j.str.2013.03.003 · Cited by 136
Di Giacomo, A. M., Calabrò, L., Danielli, R., Fonsatti, E., Bertocci, E., Pesce, I., Fazio, C., Cutaia, O., Giannarelli, D., Miracco, C., et al. (2013) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-013-1418-6 · Cited by 135
Yoshinaga, S. K., Zhang, M., Pistillo, J., Horan, T., Khare, S. D., Miner, K. T., Sonnenberg, M. G., Boone, T., Brankow, D. W., Dai, T., et al. (2000) · International Immunology · doi:10.1093/intimm/12.10.1439 · Cited by 135
Burris, H. A., Infante, J. R., Ansell, S. M., Nemunaitis, J. J., Weiss, G. R., Villalobos, V. M., Sikic, B. I., Taylor, M. H., Northfelt, D., Carson, W. E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.70.1508 · Cited by 135
Mouse B7-H3 induces antitumor immunity
Sun, X., Vale, M., Leung, E. Y., Kanwar, J. R., Gupta, R., & Krissansen, G. W. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302070 · Cited by 132
CD27-Mediated Activation of Murine NK Cells
Takeda, K., Oshima, H., Hayakawa, Y., Akiba, H., Atsuta, M., Kobata, T., Kobayashi, K., Ito, M., Yagita∥, H., & Okumura, K. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.4.1741 · Cited by 131
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity
Sakuishi, K., Apétoh, L., Sullivan, J. M., Blazar, B. R., Kuchroo, V. K., & Anderson, A. C. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.201006432011512c · Cited by 131
The CD4+ T-cell help signal is transmitted from APC to CD8+ T-cells via CD27–CD70 interactions
Feau, S., Garcia, Z., Arens, R., Yagita∥, H., Borst, J. G., & Schoenberger, S. P. (2012) · Nature Communications · doi:10.1038/ncomms1948 · Cited by 124
Tamura, H., Dan, K., Tamada, K., Nakamura, K., Shioi, Y., Hyodo, H., Wang, S.-D., Dong, H., Chen, L., & Ogata, K. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2672 · Cited by 122
Peperzak, V., Xiao, Y., Veraar, E. A. M., & Borst, J. G. (2009) · Journal of Clinical Investigation · doi:10.1172/jci40178 · Cited by 120
CD27-CD70 interactions sensitise naive CD4+ T cells for IL-12-induced Th1 cell development
van Oosterwijk, M. F., Juwana, H., Arens, R., Tesselaar, K., van Oers, M. H. J., Eldering, E., & van Lier, R. A. W. (2007) · International Immunology · doi:10.1093/intimm/dxm033 · Cited by 120
Bottai, G., Raschioni, C., Losurdo, A., Tommaso, L. D., Tinterri, C., Torrisi, R., Reis-Filho, J. S., Roncalli, M. G., Sotiriou, C. P., Santoro, A., et al. (2016) · Breast Cancer Research · doi:10.1186/s13058-016-0783-4 · Cited by 120
Ishikawa-Sekigami, T., Kaneko, Y., Okazawa, H., Tomizawa, T., Okajo, J., Saito, Y., Okuzawa, C., Sugawara-Yokoo, M., Nishiyama, U., Ohnishi, H., et al. (2005) · Blood · doi:10.1182/blood-2005-05-1896 · Cited by 119
Roberts, D. J., Franklin, N. A., Kingeter, L. M., Yagita∥, H., Tutt, A. L., Glennie, M. J., & Bullock, T. N. J. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ee238f · Cited by 118
Ligam, P., Manuelpillai, U., Wallace, E. M., & Walker, D. W. (2004) · Placenta · doi:10.1016/j.placenta.2004.08.009 · Cited by 118
Ahmed, M., Cheng, M. H., Zhao, Q., Goldgur, Y., Cheal, S. M., Guo, H.-F., Larson, S. M., & Cheung, N. V. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.679852 · Cited by 117
French, R. R., Taraban, V. Y., Crowther, G., Rowley, T. F., Gray, J. C., Johnson, P., Tutt, A. L., Al‐Shamkhani, A., & Glennie, M. J. (2007) · Blood · doi:10.1182/blood-2006-11-057216 · Cited by 116
Bossard, C., Bezieau, S., Matysiak‐Budnik, T., Volteau, C., LABOISSE, C. L., Jotereau, F., & Mosnier, J. (2011) · International Journal of Cancer · doi:10.1002/ijc.26453 · Cited by 116
Luo, L., Zhu, G., Xu, H., Yao, S., Zhou, G., Zhu, Y., Tamada, K., Huang, L., Flies, A. S., Broadwater, M., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130126 · Cited by 115
Heeren, A. M., Koster, B. D., Samuels, S., Ferns, D. M., Chondronasiou, D., Kenter, G. G., Jordanova, E. S., & de Gruijl, T. D. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0149 · Cited by 115
Wang, E., Wang, L.-C., Tsai, C., Bhoj, V. G., Gershenson, Z., Moon, E. K., Newick, K., Sun, J., Lo, A., Baradet, T. C., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0054 · Cited by 115
Takamura, S., Tsuji-Kawahara, S., Yagita∥, H., Akiba, H., Sakamoto, M., Chikaishi, T., Kato, M., & Miyazawa, M. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903478 · Cited by 111
LICOS, a primordial costimulatory ligand?
Brodie, D. W., Collins, A. V., Iaboni, A., Fennelly, J. A., Sparks, L. M., Xu, X.-N., van der Merwe, P. A., & Davis, S. J. (2000) · Current Biology · doi:10.1016/s0960-9822(00)00383-3 · Cited by 111
Human KIR repertoires: shaped by genetic diversity and evolution
Manser, A., Weinhold, S., & Uhrberg, M. (2015) · Immunological Reviews · doi:10.1111/imr.12316 · Cited by 108
Rowley, T. F., & Al‐Shamkhani, A. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.10.6039 · Cited by 108
Powderly, J. D., Cote, G. M., Flaherty, K. T., Szmulewitz, R. Z., Ribas, A., Weber, J. S., Loo, D. T., Baughman, J. E., Chen, F., Moore, P. A., et al. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/2051-1426-3-s2-o8 · Cited by 107
He, L.-Z., Prostak, N., Thomas, L. J., Vitale, L. A., Weidlick, J., Crocker, A., Pilsmaker, C. D., Round, S. M., Tutt, A., Glennie, M. J., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1300409 · Cited by 104
Demeure, C. E., Wolfers, J., Martin‐Garcia, N., Gaulard, P., & Triebel, F. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00184-8 · Cited by 104
The clinical impact of ICOS signal in colorectal cancer patients
Zhang, Y., Luo, Y., Qin, S., Mu, Y., Yang, Q., Yu, M., & Zhong, M. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1141857 · Cited by 104
Deuss, F. A., Gully, B. S., Rossjohn, J., & Berry, R. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m117.786483 · Cited by 104
B7‐H3 promotes acute and chronic allograft rejection
Wang, L., Fraser, C. C., Kikly, K. K., Wells, A. D., Han, R., Coyle, A. J., Chen, L., & Hancock, W. W. (2005) · European Journal of Immunology · doi:10.1002/eji.200425518 · Cited by 102
Kim, M. J., Lee, J.-C., Lee, J., Kim, S., Lee, S. G., Park, S., Sung, M. W., & Heo, D. S. (2008) · Tumor Biology · doi:10.1159/000132568 · Cited by 101
ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28
Hutloff, A., Dittrich, A., Beier, K. C., Eljaschewitsch, B., Kraft, R., Anagnostopoulos, I., & Kroczek, R. A. (1999) · Nature · doi:10.1038/35005523 · Cited by 99
Peperzak, V., Veraar, E. A. M., Xiao, Y., Bąbała, N., Thiadens, K. A. M. H., Brugmans, M., & Borst, J. G. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202222 · Cited by 98
Cited by
A guide to cancer immunotherapy: from T cell basic science to clinical practice
Waldman, A. D., Fritz, J. M., & Lenardo, M. J. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0306-5 · Cited by 4,154
Deng, Q., Han, G., Puebla-Osorio, N., Ma, M. C. J., Strati, P., Chasen, B., Dai, E., Dang, M., Jain, N., Yang, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1061-7 · Cited by 600
Gangoso, E., Southgate, B., Bradley, L., Rus, S., Galvez-Cancino, F., McGivern, N., Güç, E., Kapourani, C.-A., Byron, A., Ferguson, K. M., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.023 · Cited by 359
NK Cell-Based Immune Checkpoint Inhibition
Khan, M., Arooj, S., & Wang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00167 · Cited by 356
FoxP3+ T regulatory cells in cancer: Prognostic biomarkers and therapeutic targets
Saleh, R., & Elkord, E. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.07.022 · Cited by 352
Metadata
- Authors
- Burugu, S., Dancsok, A. R., & Nielsen, T. O.
- Venue
- Seminars in Cancer Biology
- Publisher
- Elsevier BV
- Published
- 2018-10
- Volume
- 52
- Issue
- Pt 2
- Pages
- 39-52
- ISSN
- 1044-579X (ISSN-L)
- OpenAlex
- W2761081415
- Cited by
- 314
- References
- 282
- FWCI
- 11.74
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.